Aquestive(AQST) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues increased to $13 million in Q4 2025 from $11.9 million in Q4 2024, a 10% increase primarily driven by manufacture and supply revenue growth [18][19] - Full year 2025 total revenues decreased to $44.5 million from $57.6 million in 2024, a decline of 22.5% due to the one-time recognition of deferred revenues in the prior year [19][26] - R&D expenses decreased to $3.2 million in Q4 2025 from $4.9 million in Q4 2024, and for the full year, R&D expenses decreased to $17.2 million from $20.3 million [20][21] - Selling, general and administrative expenses increased to $32.8 million in Q4 2025 from $16 million in Q4 2024, primarily due to higher legal expenses and commercial spending [22][23] - Net loss for Q4 2025 was $31.9 million, compared to a net loss of $17.1 million in Q4 2024 [24][26] - Cash and cash equivalents as of December 31, 2025, were $121.2 million, with a guidance for 2026 total revenue of $46 million to $50 million [28][29] Business Line Data and Key Metrics Changes - Manufacture and supply revenue increased to $12 million in Q4 2025 from $10.7 million in Q4 2024, driven by increases in Suboxone and Ondif revenues [19] - Full year manufacture and supply revenue increased slightly to $40.2 million from $40 million in 2024, primarily due to increases in Ondif revenues [20] Market Data and Key Metrics Changes - The overall allergy market grew by just over 9% in Q4 2025, with EpiPen and generic auto injectors growing by approximately 5% [13] - Over 90% of prescriptions remain with auto-injectors, indicating a strong market preference for medical devices [14] Company Strategy and Development Direction - The company is focused on launching Anaphylm, with plans to file in Europe and Canada by the end of the year and to meet with the U.K. Health Authority [11] - The commercial strategy includes launching with 75 sales representatives, 50% more than previously planned, to enhance market penetration [12][42] - The company is also prioritizing out-licensing activities for Libervant and exploring partnerships for Anaphylm in international markets [15][90] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's future, citing a clear path for Anaphylm's market entry and a strong clinical team [8][10] - The management highlighted the importance of capital access for the drug launch and noted the extension of a revenue sharing agreement with RTW [13][18] - The company anticipates a non-GAAP adjusted EBITDA loss of $30 million to $35 million for 2026, reflecting ongoing costs associated with Anaphylm's NDA resubmission and pre-commercial activities [29][30] Other Important Information - The company reached a settlement in a long-standing defamation lawsuit, which is expected to reduce distractions from the business [14] - The FDA's recent denial of a competitor's citizen petition was seen as a validation of the company's data package [64] Q&A Session Summary Question: Confirmation of Type A meeting with the FDA - The company confirmed that a Type A meeting request has been submitted and is expected to occur within 30 days [32][33] Question: Goals for the FDA meeting - The goals include ensuring alignment on executing the requested studies and clarifying any minor protocol modifications [32][34] Question: RTW agreement extension - The extension until June 30, 2027, was made for flexibility, and the terms of the agreement remain unchanged [39][40] Question: Sales force expansion rationale - The decision to increase sales reps was driven by the need for deeper market penetration and greater efficiency in reaching key physicians [42][44] Question: Future clinical development of AQST-108 - The company indicated that AQST-108's development will be prioritized after Anaphylm's resubmission, but both projects are linked [86][87] Question: Promotional campaign adjustments - The company is refining its launch plan but does not anticipate fundamental changes in messaging or strategy [82][83] Question: Updates on the citizen petition and AAAAI conference takeaways - The FDA denied a competitor's petition, validating the company's data, and feedback from the AAAAI conference indicated strong interest in Anaphylm [64][66]